BPTH RSI Chart
Last 7 days
-16.7%
Last 30 days
-23.3%
Last 90 days
-73.0%
Trailing 12 Months
58.1%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 18, 2019 | armistice capital, llc | sold | - | - | - | - |
Jan 18, 2019 | armistice capital, llc | sold | -171,643 | 2.6629 | -64,457 | - |
Which funds bought or sold BPTH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | sold off | -100 | -6,034 | - | -% |
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -324 | - | -% |
May 15, 2024 | MORGAN STANLEY | new | - | 144 | 144 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -70.00 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 29.00 | 29.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -4,502 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 7,968 | 7,968 | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -11,202 | - | -% |
May 14, 2024 | NORTHERN TRUST CORP | sold off | -100 | -8,200 | - | -% |
Unveiling Bio-Path Holdings Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bio-Path Holdings Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
Bio-Path Holdings Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -45.1% | 2.00 | 3.00 | 5.00 | 7.00 | 11.00 | 16.00 | 19.00 | 21.00 | 24.00 | 27.00 | 31.00 | 31.00 | 33.00 | 16.00 | 15.00 | 18.00 | 20.00 | 23.00 | 18.00 | 19.00 | 21.00 |
Current Assets | -46.2% | 2.00 | 3.00 | 5.00 | 6.00 | 11.00 | 16.00 | 18.00 | 21.00 | 24.00 | 26.00 | 30.00 | 31.00 | 33.00 | 16.00 | 14.00 | 17.00 | 19.00 | 22.00 | 17.00 | 19.00 | 21.00 |
Cash Equivalents | -82.1% | 0.00 | 1.00 | 2.00 | 3.00 | 7.00 | 10.00 | 14.00 | 17.00 | 21.00 | 24.00 | 27.00 | 28.00 | 31.00 | 14.00 | 12.00 | 14.00 | 18.00 | 20.00 | 15.00 | 17.00 | 19.00 |
Net PPE | -28.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 58.1% | 4.00 | 3.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 |
Current Liabilities | 100.0% | 4.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Shareholder's Equity | -695.2% | -2.62 | 0.00 | 3.00 | 5.00 | 9.00 | 14.00 | 16.00 | 20.00 | 22.00 | 25.00 | 29.00 | 30.00 | 31.00 | 15.00 | 13.00 | 16.00 | 18.00 | 21.00 | 16.00 | 18.00 | 20.00 |
Retained Earnings | -2.9% | -110 | -107 | -104 | -101 | -96.80 | -91.53 | -87.56 | -84.03 | -81.02 | -77.66 | -73.54 | -71.48 | -69.67 | -67.22 | -64.67 | -61.70 | -59.66 | -56.34 | -53.95 | -51.71 | -49.25 |
Additional Paid-In Capital | 0.1% | 108 | 108 | 107 | 106 | 106 | 106 | 104 | 104 | 103 | 103 | 103 | 101 | 101 | 82.00 | 78.00 | 78.00 | 78.00 | 77.00 | 70.00 | 70.00 | 69.00 |
Accumulated Depreciation | 2.1% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Shares Outstanding | 22.0% | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 14.00 | - | - | - | 28.00 | - | - | - | 46.00 | - | - | - | 18.00 | - | - | - | 37.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 42.8% | -1,038 | -1,814 | -2,781 | -3,287 | -3,653 | -5,000 | -3,374 | -4,203 | -2,526 | -2,801 | -2,891 | -2,653 | -1,572 | -2,592 | -2,353 | -3,480 | -2,535 | -2,245 | -1,893 | -2,215 | -2,008 |
Share Based Compensation | -5.6% | 170 | 180 | 178 | 170 | 206 | 209 | 212 | 213 | 217 | 230 | 262 | 189 | 140 | 145 | 143 | 119 | 170 | 162 | 184 | 181 | 157 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | -23.00 | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | -66.1% | 174 | 514 | - | - | - | - | - | - | - | -3.00 | 1,399 | - | 18,610 | 4,289 | - | - | - | 7,289 | 169 | 45.00 | 20,280 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 2,288 | $ 3,989 |
General and administrative | 1,407 | 1,303 |
Total operating expenses | 3,695 | 5,292 |
Net operating loss | (3,695) | (5,292) |
Other income | ||
Change in fair value of warrant liability | 538 | |
Interest income | 19 | |
Total other income | 538 | 19 |
Net loss | $ (3,157) | $ (5,273) |
Net Loss Per Share, Basic | ||
Net loss per share, basic | $ (4.88) | $ (13.25) |
Weighted average number of common shares outstanding, basic | 647 | 398 |
Net Loss Per Share, Diluted | ||
Net loss per share, diluted | $ (4.88) | $ (13.25) |
Weighted average number of common shares outstanding, diluted | 647 | 398 |
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash | $ 188 | $ 1,052 |
Prepaid drug product | 632 | 632 |
Other current assets | 817 | 1,358 |
Total current assets | 1,637 | 3,042 |
Fixed assets | ||
Furniture, fixtures & equipment | 1,120 | 1,120 |
Less accumulated depreciation | (1,066) | (1,044) |
Fixed assets, net | 54 | 76 |
Right of use operating assets | 77 | 102 |
Total Assets | 1,768 | 3,220 |
Current liabilities | ||
Accounts payable | 1,746 | 457 |
Accrued expenses | 1,984 | 1,346 |
Current portion of lease liabilities | 82 | 103 |
Total current liabilities | 3,812 | 1,906 |
Warrant liability | 578 | 863 |
Noncurrent lease liabilities | 3 | 10 |
Total Liabilities | 4,393 | 2,779 |
Shareholders' equity | ||
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding | ||
Common stock, $.001 par value; 200,000 shares authorized; 754 and 398 shares issued and outstanding, respectively | 1 | 1 |
Additional paid in capital | 108,138 | 108,047 |
Accumulated deficit | (110,764) | (107,607) |
Total shareholders' equity | (2,625) | 441 |
Total Liabilities & Shareholders' Equity | $ 1,768 | $ 3,220 |